Anti-hIL-28b-IgG Neutralizing monoclonal antibody against human 28b Catalog # mabg-hil28b-3

For research use only, not for diagnostic or therapeutic use Version # 15C16-MM

PRODUCT INFORMATION DESCRIPTION Content: 3 x 100 µg purified anti-hIL-28b-IgG antibody, provided Anti-hIL-28b-IgG is a monoclonal antibody specific for human azide-free and lyophilized interleukin 28B (hIL-28B). This antibody has been selected for its Target: natural and recombinant human IL-28B ability to efficiently neutralize the biological activity of hIL-28B . Specificity: No cross -reactivity with human IL-28A, mouse IL-28A Anti -hIL -28b -IgG is produced in hybridomas and purified by affinity or mouse IL-28B. chromatography. Clone: 18F4 Isotype: Mouse IgG1 APPLICATIONS Immunogen: Human IL-28B protein expressed in Swiss mice Anti-hIL-28b-IgG is a neutralizing antibody, it blocks hIL-28B- following DNA immunization induced cellular activation. Other applications have not been tested. Formulation: 0.2 mm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents Neutralization Antibody resuspension The exact concentration of antibody required to neutralize hIL-28B Add 1 ml of sterile water per vial to obtain a concentration of 0.1 mg/ml. activity is dependent on the concentration, cell type and Storage growth conditions. InvivoGen has determined the neutralization dose - Product is shipped at room temperature. Store lyophilized antibody for this antibody using recombinant hIL-28B and HEK -Blue ™ IFN -a/b at -20 °C. Product is stable for at least 1 year. cells. These cells were generated by stable transfection of HEK293 - Reconstituted antibody is stable for 1 month when stored at 4 °C and cells with the human STAT2 and IRF9 to obtain a fully active for 1 year when aliquoted and stored at -20 °C. Avoid repeated type I IFN signaling pathway. They were further transfected with a freeze-thaw cycles. SEAP (secreted embryonic alkaline phosphatase) reporter under Quality control the control of the IFN- α/β inducible ISG54 promoter . - This product has been validated for neutralization. Anti-hIL-28b-IgG (30 ng-1 mg/ml) and a negative control antibody - The absence of bacterial contamination (e.g. lipoproteins and (e.g. Mouse IgG1 Control which targets E. coli β-galactosidase) were endotoxins) has been confirmed using HEK-Blue ™ TLR2 and ™ incubated with recombinant hIL-28B at 10 ng/ml for 30 min prior to HEK -Blue TLR4 cells. the addition of the HEK-Blue ™ IFN- a/b cells . Neutralization of IL -28B-induced signaling by anti-hIL-28b-IgG was determined after BACKGROUND a 24-hour incubation by assessing SEAP production using Interleukin-28 (IL-28) is a member of the type III interferon (IFN QUANTI -Blue ™, a SEAP detection reagent. QUANTI-Blue ™ turns lambda) cytokine family that exhibits several common features with blue following cytokine stimulation but remains pink if neutralization 1, 2 type I IFNs: antiviral activity and antitumor activity . IL-28 exerts its occurs. SEAP levels can be assessed by the naked eye or action following binding to a heterodimeric protein complex spectrophotometrically by reading the optical density at 620 -655 nm. composed of two subunits, IL-28 receptor alpha and IL-10 receptor beta, leading to signaling through the Jak/Stat pathway and inducing RELATED PRODUCTS the expression of IFN-stimulated genes. IL-28 comes in two isoforms, IL-28A (also known as interferon lambda 2) and IL-28B (also known Product Catalog Code as ). Genetic variation in the IL-28B gene, which codes for the IL-28B isoform, is associated with an altered immune ™ a/b 3 HEK-Blue IFN- Cells hkb-ifnab response to certain viruses, including hepatitis C . Mouse IgG1 Control mabg1-ctrlm ™ 1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. QUANTI-Blue rep-qb1 J Interferon Cytokine Res. 30(8):555-64. 2. Li M. et al., 2009. Interferon -ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32. 3. Hajarizadeh B. et al., 2014. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol. 61(3):430-4. 4. Donnelly RP. et al., 2011. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 32(9):443-50.

TECHNICAL SUPPORT InvivoGen USA (Toll‑Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 www.invivogen.com InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong : +852 3-622-34-80 E-mail: [email protected]